Introduction
============

Metastasis is a process through which cancer cells dissociate from the primary tumor site, invade the surrounding tissue, hijack the circulation as a means of transport, and ultimately reconstitute the tumor at a secondary site. This process constitutes over 90% of cancer-associated deaths despite significant advances in cancer treatment^\[[@R1]\]^. Epithelial-mesenchymal transition (EMT) is critical during embryo development and organogenesis. Aberrant activation of EMT is thought to promote tumor dissociation, migration, and cancer stem cell enrichment in multiple forms of cancer^\[[@R2]--[@R5]\]^. These mesenchymal-like tumor cells migrate from the tumor front, through the basement membrane and into circulation where they are referred to as circulating tumor cells (CTCs)^\[[@R6]\]^. A small number of CTCs display cancer stem cell (CSC) features such as immune evasion, invasiveness, tumorigenicity, and resistance to different treatments^\[[@R7]\]^. Once the CSCs reach a suitable secondary tumor site, they undergo a reverse process, mesenchymal-epithelial transition (MET), halting migration and allowing reconstitution of tumor at the secondary site (***Fig. 1A***)^\[[@R10]-[@R11]\]^.

Fig.1Schematic diagram of hybrid E/M and classical EMT/MET CSCs.The classic EMT/MET model of metastasis which was coined in 1976^\[[@R8]\]^. Mesenchymal cancer cells including CSCs are transformed from epithelial state through an EMT process. They then migrate outside the primary tumor, pass through the basement membrane and enter circulation. When mesenchymal CSCs reach a suitable secondary site prior to development of a new tumor, they undergo MET to regain an epithelial phenotype for tumor development. (B) The hybrid E/M theory was first succinctly formulated in 2006^\[[@R9]\]^. These hybrid cancer cells including CSCs migrate from the primary tumor alone or in clusters together with epithelial or mesenchymal tumor CSCs by crossing the basement membrane to enter the circulation system and then relocate to a suitable secondary tumor site. Secondary tumor may develop from the hybrid E/M CSCs, epithelial tumor CSCs present in the cluster or mesenchymal CSCs that undergo MET.

This classic and simplified view of metastasis, during past several decades, has geared research toward targeting the migrating mesenchymal cancer cells^\[[@R12]--[@R17]\]^. However, controversy has surrounded this model^\[[@R18]--[@R22]\]^ which does not take into consideration of cellular plasticity, the tumorigenicity of epithelial cells, the full extent of tumor niches involved in EMT induction, the possibility of co-migration of both epithelial and mesenchymal cells, and hybrid epithelial-mesenchymal (E/M) tumor cells (***Fig. 1B***). By addressing these deficiencies, a new model may lead to novel strategies to treat cancer metastasis and progression.

A general overview of classical EMT/MET and their regulators
============================================================

The classical EMT process in cancer encompasses the gradual remodeling of epithelial-like tumor cells toward a mesenchymal-like phenotype. Mesenchymal traits include the repression of epithelial markers, enrichment of mesenchymal markers, enrichment of the CD44^high^/CD24^low^ CSC population, absence of cellular polarity due to the re-arrangement of actin cytoskeleton and re-distribution of adhesion molecules, individualistic migration, and resistance to apoptosis^\[[@R23]--[@R28]\]^. Epithelial traits, on the other hand, are opposite to the mesenchymal traits and exhibit some additional features such as enriched ALDH+ CSC subpopulation and collective migration^\[[@R29]--[@R31]\]^.

In literature, EMT is commonly characterized by decreased *E*-cadherin expression. *E*-cadherin binds to neighboring cadherins through its extracellular domain, mediating cell-cell adhesion, preventing tumor cell migration and *in vivo* dissemination/invasiveness^\[[@R32]-[@R33]\]^. The intracellular domain of *E*-cadherin binds to β-Catenin (an effector of Wnt signaling), preventing the nuclear translocation of β-catenin and β-catenin/T cell factor (TCF)-mediated transactivation, impeding Wnt signaling and acquisition of mesenchymal traits^\[[@R34]-[@R35]\]^. In addition to *E*-cadherin repression, the mesenchymal markers vimentin and N-cadherin are upregulated and EMT transcription factors (EMT-TF), such as SNAIL, SLUG, ZEB and TWIST are also upregulated. These transcription factors inhibit the epithelial phenotypes of the tumor cells while promoting acquisition of the mesenchymal phenotype through a plethora of incompletely defined mechanisms, including microRNA networks^\[[@R36]\]^, protein stabilization^\[[@R37]\]^, gene expression^\[[@R38]\]^, epigenetic/chromatin modification^\[[@R39]\]^ and long non-coding RNA regulation^\[[@R40]\]^. SNAIL and SLUG both inhibit *E*-cadherin expression, promoting β-catenin nuclear translocation and subsequent Wnt pathway upregulation^\[[@R41]-[@R42]\]^. In addition, they promote the formation of the β-catenin--TCF4 transcription complex which binds to the *TGF-*β*3* gene promoter and promoting its expression which in turn further stimulates Wnt signaling through *LEF1* gene expression, ultimately enhancing acquisition of mesenchymal traits^\[[@R43]-[@R44]\]^. TGF-β signaling also stimulates zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) which bind to phosphorylated receptor-activated Smads^\[[@R45]\]^ and various transcription factors as well as histone acetyltransferases such as p300 and p/CAF, leading to epigenetic modification of gene expression^\[[@R46]\]^. Similarly, TWIST affects a large number of transcriptional processes, overrides oncogene-induced senescence and represses *E*-cadherin while promoting *N*-cadherin expression^\[[@R47]-[@R48]\]^. TWIST is notably activated through hypoxia-inducible factor 1α under intratumoral hypoxic conditions^\[[@R49]\]^, a trait associated with chemotherapy resistance^\[[@R50]\]^. These EMT-TFs may work together through overlapping and distinct molecular mechanisms to regulate a complex network in tumor cells to control epithelial versus mesenchymal plasticity.

In addition, various biologic processes such as inflammation within the tumor microenvironment mediate EMT. When breast epithelial cells, adjacent to the tumor, were exposed to inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) for 2-3 weeks, ZEB1 and SNAIL (two major EMT transcription factors) were significantly upregulated^\[[@R51]\]^. The exposed breast epithelial cells then displayed upregulated matrix metalloproteinases (MMPs, capable of degrading the basement membrane to facilitate tumor cell migration)^\[[@R52]-[@R53]\]^ and increased migratory/invasive capabilities, suggesting that tumor microenvironment influences plasticity and tumor cell dissemination by promoting EMT^\[[@R51]\]^.

More recently, mesenchymal stem cells (MSC) from human adipose tissue have been shown to produce soluble factors after exposure to interferon-γ (IFN-γ) or TNF-α to enhance the malignancy of the MCF-7 breast cancer cells and shift the cells toward a mesenchymal phenotype with increased migration capacity, enhanced vimentin expression and decreased *E*-cadherin expression^\[[@R54]\]^.

It has been found that bacteria can influence the tumor microenvironment and promote EMT. When gastric cancer cells were exposed to *H. pylori-*infected MSC supernatant enriched with IL-6 (interleukin-6), IL-8 and platelet-derived growth factor-β cytokines, a mesenchymal phenotype was induced, characterized by increased migration, *N*-cadherin and vimentin expression while decreased *E*-cadherin expression^\[[@R55]\]^.

Paracrine/autocrine signaling within the tumor in response to chemotherapy has also been associated with EMT promotion. IL-6, IL-8 and monocyte chemoattractant protein-1 (MCP-1) cytokines along with NF-κB/IκBa and STAT3 (Signal transducer and activator of transcription 3) were found to be upregulated in triple negative breast cancer cells after exposure to commonly prescribed chemotherapeutics, leading to upregulation of stem cell-associated gene and protein expression, enrichment of CD44^high^/CD24^low^ cancer stem-like cells, and enhanced tumorigenicity in nude mice^\[[@R56]\]^.

Together, identification of signaling pathways and factors capable of regulating EMT has been the focus of considerable research during the past several decades in hopes that through prevention of EMT-mediated migration, tumor metastasis would have been halted^\[[@R12]--[@R17]\]^.

From classical EMT/MET to the hybrid EMT/MET model
==================================================

There is a plethora of literature in regards to EMT, tumor dissemination and migration through the surrounding tissue into the bloodstream and other organs. However, proof of MET at a metastatic site from a re-localized mesenchymal CTC has not yet been proved, challenging the classical EMT/MET theory regarding mesenchymal to epithelial conversion in the secondary tumor site^\[[@R57]\]^. Additional arguments against classical EMT theory in metastasis and clinical applicability are the methodologies used and data generated from transgenic mice^\[[@R58]\]^, xenograft implantation^\[[@R59]\]^, and *in vitro* petri dish work^\[[@R59]\]^. These experimental results are seemingly incompatible with pathological observations obtained from patients' tissues^\[[@R60]\]^. Some tumors even exhibit opposite characteristics based on EMT/MET markers. For instance, in prostate cancer, secondary tumors with highly metastatic potential were found to possess a glandular appearance indicative of epithelial morphology^\[[@R61]\]^. A similar phenotype is displayed in ovarian cancer which possesses elevated *E*-cadherin expression and an epithelial phenotype yet is highly metastatic^\[[@R62]--[@R65]\]^.

To tackle the clinical applicability of EMT, lineage tracing is required. Recent reports addressed this issue by generating a mesenchymal promoter (vimentin or fibroblast specific protein-1)-induced Cre-mediated fluorescent marker in breast and lung cancer^\[[@R21]\]^. The cells would irreversibly gain fluorescence *in vivo* upon induction of a mesenchymal phenotype through EMT. The mice spawned breast adenocarcinoma, which predominantly exhibited an epithelial phenotype based on *E*-cadherin expression and lacked vimentin and fluorescence expression. Lung metastasis developed spontaneously in the mouse models, which exhibited no change in fluorescence, indicating the same epithelial phenotype within the secondary tumor (confirmed via *E*-cadherin upregulation and vimentin repression), demonstrating that tumor cells did not activate the mesenchymal-specific promoter or undergo EMT during metastasis^\[[@R21]\]^.

Additionally, another study developed a genetically engineered mouse model to delete SNAIL or TWIST through Cre-mediation in pancreatic ductal adenocarcinoma (PDAC)^\[[@R22]\]^. Significantly, this deletion supressed ZEB2 and enhanced *E*-cadherin expression in PDAC. Lineage tracing by determining the amount of yellow fluorescent protein-tagged CTCs in the control versus SNAIL or TWIST-deletion groups showed that tumor-forming potential and metastatic capacity were not affected. These results indicate that suppression of EMT-TF in PDAC mouse models did not impede tumor invasion, metastasis or dissemination when tumor cells exhibit an epithelial phenotype^\[[@R22]\]^.

The aforementioned studies challenge the classical EMT model in metastasis and tumor dissemination, suggesting that EMT does not correlate with tumor dissemination and metastasis and that tumor cells with epithelial phenotypes expressing high level of *E*-cadherin can undergo metastasis and form secondary tumors. Although these studies use one or two core EMT related genes or EMT-TF and possibly simplify EMT processes, the findings support an incomplete, partial or hybrid EMT model to explain metastasis without losing epithelial properties and the formation of secondary tumor without interconvertible epithelial to mesenchymal transitions.

Hybrid E/M and clinical relevance
=================================

EMT is currently characterized according to the upregulated mesenchymal and repressed epithelial markers in combination with functional tests for tumor cell migration and dissemination. It is assumed that cells undergoing EMT completely switch from the epithelial to the mesenchymal phenotypes. Increasing experimental evidence, however, suggests that this switch is not a single binary decision, but rather proceeds along a spectrum, allowing for cells to express partial epithelial and mesenchymal (E/M) phenotypes and possess both E/M functionality^\[[@R65]--[@R67]\]^.

Indeed, hybrid E/M states (i.e. exhibiting both epithelial and mesenchymal characteristics) have been observed in breast, brain, lung, renal, prostate and pancreatic cancers^\[[@R67]--[@R72]\]^. Moreover, the hybrid E/M tumor cells display elevated CSC properties and patients show poor survival in comparison to EMT or MET phenotypes, possibly through synergy between adhesion, proliferation and migration in the E/M state^\[[@R66]\]^. In breast, prostate and lung cancer patients, CTCs with E/M markers were found to migrate into blood as clusters^\[[@R73]--[@R76]\]^. This collective migration would reduce anoikis and increase the chances of successful migration to a suitable secondary tumor location^\[[@R77]\]^. These attributes may explain why clustered CTCs exhibit a 50-fold increase in metastatic potential^\[[@R78]\]^. Hence, a better understanding of E/M properties may be key to development of an effective therapeutic strategy to control metastasis and disease relapse (***Fig. 1B***).

Literature, however, has put the stability of the hybrid E/M tumor phenotype into question. Are these E/M tumor cells stable or is hybrid E/M tumor phenotype a fluctuating transition? Previously, E/M tumor cells were considered metastable and incapable of maintaining their E/M properties. The hybrid phenotype was thought merely a placeholder along the pathway of complete EMT or MET conversion. Recently, studies using prostate, lung and breast cancer have illustrated that this duel E/M phenotype, mediated through OVOL (OVO-like proteins) transcription, can be maintained for the extended periods of time^\[[@R79]-[@R80]\]^. OVOL are a series of transcription factors (originally found through mathematical models) which play a critical role in maintaining the E/M prostate CTCs through regulation of the miR-200/ZEB and miR-34/SNAIL pathways. OVOL expression led to decreased EMT signaling induced by factors such as TGF-β, and promoted a stable shift toward the epithelial and hybrid E/M phenotype^\[[@R79]\]^.

Additional mathematical modeling has identified that GRHL2 and miR-145 can also stabilize the hybrid E/M phenotype^\[[@R80]\]^. Hybrid E/M lung cancer cells were able to be maintained through GRHL2, OVOL2 and miR-145 expression that act as stabilizing factors to inhibit themselves and the ZEB/miR-200 network. Knocking down miR-145 or GRHL2 led to destabilization of the E/M phenotype, driving the cells toward complete EMT induced by SNAIL^\[[@R80]\]^.

Other reports have also emphasized the importance of the miR-34/SNAIL and the miR-200/ZEB regulatory networks^\[[@R81]\]^. Mechanistic modeling has shown that SNAIL is able to inhibit miR-200 while ZEB is able to inhibit miR-34. As such, miR-34/SNAIL activation drives ZEB expression while inhibiting miR-200 leads to three states: high miR-200/low ZEB, low miR-200/high ZEB or medium miR-200/medium ZEB^\[[@R81]\]^. These states are associated with epithelial, mesenchymal or hybrid phenotypes, respectively. E/M stabilizing factors OVOL, GRHL2 and miR-145 couple with this network, prevent ZEB signaling and promote miR-200, which inhibits complete EMT while pushing cells toward an epithelial and hybrid E/M phenotype^\[[@R79]--[@R81]\]^.

Signaling pathways also affect the balance of miR-200/ZEB. For instance, NF-κB drives the LIN28/let-7 axis^\[[@R82]\]^ and LIN28 inhibits let-7 which in turn inhibits ZEB^\[[@R82]\]^, whereas Let-7 and miR-200 inhibit LIN-28 and bridge two networks^\[[@R82]\]^. It has been found that low LIN-28 and high let-7 correlated with an epithelial phenotype while high LIN-28 mediated Let-7 inhibition and pushed cells toward a mesenchymal phenotype^\[[@R82]\]^. The hybrid E/M phenotype displayed intermediate expression of LIN28 and let-7^\[[@R82]\]^. Additionally, the LIN-28/let-7 axis regulates stemness through OCT4 expression^\[[@R83]\]^. An outline of hybrid E/M signaling and stemness acquisition is depicted in ** ***Fig. 2***.

Fig.2A schematic diagram of hybrid E/M signaling and stemness acquisition.The acquisition of mesenchymal traits is associated with increased ZEB signaling. ZEB feed-forwarding signaling inhibits miR-200 and leads to the expression of mesenchymal markers such as Ncadherin and vimentin while repressing epithelial associated markers such as E-cadherin. Snail upregulates ZEB while inhibiting miR-34. In addition, Snail is stimulated by many signaling pathways including NF-κβ, Wnt, c-Myc and HIF1-α. LIN-28 is also associated with the acquisition of mesenchymal traits. LIN-28 inhibits Let-7, increasing ZEB expression while also promoting OCT-4 and enhancing stemness. The acquisition of epithelial traits is associated with high levels of miR-200 and miR-34 which repress ZEB and Snail, respectively. MiR-200 also represses LIN-28 signaling, promoting Let-7 expression to further repress ZEB and promote OCT-4 and other stemness feature. Additionally, miR-200 inhibits LIN-28 to increase Let-7 expression, ultimately repressing mesenchymal while promoting epithelial phenotypes. The hybrid E/M phenotype is associated with intermediate signaling between miR-200/ZEB, miR-34/Snail and Let-7/LIN28 axes, which is associated with intermediate OCT-4 expression and the greatest stemness potential. OVOL, GRHL2, and miR-145 are hybrid E/M modulators, stabilizing the hybrid E/M phenotype, inhibiting ZEB signaling and complete EMT. These stabilizers also promote hybrid E/M stemness.

Further studies have shown that the acquisition of stemness can be modulated in mesenchymal, epithelial and hybrid E/M. For instance, OVOL enhanced hybrid E/M stemness while reducing mesenchymal stemness^\[[@R82]\]^. On the contrary, OVOL repression exerted an opposite effect, enhancing mesenchymal while diminishing epithelial and hybrid E/M stemness^\[[@R82]-[@R83]\]^. It would be interesting to determine whether or not the Wnt, Akt, YAP, and/or other signaling pathways, known in EMT/MET regulation and stemness, are involved in the miR-200/ZEB and/or LIN28/let-7 axis and associated with hybrid E/M formation, and/or involved in acquisition of stemness properties.

Investigation of hybrid E/M with improved methodologies
=======================================================

Studying hybrid E/M cancer cells proves to be challenging since these cells possess both epithelial and mesenchymal markers and functions. *In vitro* cell culture may produce inconsistent results due to artificial selection of monoculture from thriving cell sublines. Moreover, lack of microenvironment, extracellular matrix and three dimensions add to the discrepancy between *in vitro* and *in vivo* results. However, advances in the development of *in vitro* 3D cell culture systems have led to new discoveries in regards to cancer cell plasticity between epithelial, mesenchymal, and hybrid E/M states.

Recently, coculture of mammary EpH4 epithelial cells with a bio-engineered 3D matrix composed of solid alginate hydrogel with adhesive RGD (Arg-Gly-Asp) peptides replicated a 3D microenvironment, leading to normal epithelial morphogenesis and producing acini-like structures, native to mammary tissue^\[[@R84]\]^. TGFβ1 was then used to promote EMT where mesenchymal cells were generated, but upon removal of TGFβ1, the cells switched to the hybrid E/M phenotype instead of an epithelial state. Notably, these hybrid cells displayed increased proliferative and tumorigenic capabilities and an aggressive phenotype^\[[@R84]\]^.

The usage of microfluidic coculture systems for tumor microenvironment emulation has also been demonstrated to be an effective methodology for analysis of epithelial/mesenchymal/hybrid traits^\[[@R85]--[@R88]\]^. This platform can analyze cancer cells in an extracellular matrix and assess proliferation, dissemination and migration in real time. Activators/repressors can be introduced into the coculture system to stimulate epithelial or mesenchymal phenotypes, and thus enable cellular communication to mimic *in vivo* processes. With further innovation, this system may be invaluable for further investigation of epithelial/mesenchymal and hybrid E/M characters in real time using lineage tracing with promoter-induced fluorescent proteins as described above.

Marker analysis may also be a useful tool for hybrid E/M research. Besides the dual epithelial and mesenchymal gene and protein expression, *P*-cadherin has been gaining traction as a hybrid E/M marker^\[[@R80],\ [@R89]-[@R90]\]^. *P*-cadherin is associated with poor prognosis in breast, oral squamous, bladder, pancreatic and ovarian cancers^\[[@R91]--[@R95]\]^. It interferes with epithelial adhesion and promotes migration and metastasis through MMP upregulation, cell polarization, CDC42 (cell division control protein 42 homolog) activation, and its own cleavage^\[[@R89]-[@R90],\ [@R96]-[@R97]\]^. Importantly, *P*-cadherin-promoted migration is through collective but not individual cell movement in both epithelial and mesenchymal cancer cells, mimicking the hybrid E/M phenotype^\[[@R80],\ [@R89]-[@R90]\]^.

CD44^high^/CD24^low^/ALDH^high^ markers may also be employed for the identification of hybrid E/M CSCs. CD44^high^/CD24^low^ subpopulation are commonly enrich-ed in mesenchymal-like cancer cells while ALDH^high^ is enriched in epithelial-like cancer cells^\[[@R98]-[@R99]\]^. It has been shown *in vivo* in breast cancer that the ALDH^high^ subpopulation resides internally while the CD44^high^/CD24^low^ tumor population lies at the tumor edge and is prone for tumor dissemination and metastasis^\[[@R30]\]^. The CD44^high^/CD24^low^/ALDH^high^ subpopulation in multiple breast cancer cell lines exhibited the enhanced proliferative, tumorigenic, migration, adhesive and metastatic potentials both *in vitro* and *in vivo*^\[[@R30],\ [@R100]--[@R102]\]^. Moreover, the CD44^high^/CD24^low^/ALDH^high^ subpopulation is able to generate tumors with as few as 20 cells^\[[@R101]\]^. This is consistent with the clinical data where ALDH^high^/ CD44^high^ is frequently found in patients with breast cancer and associated with increased tumor growth, disease progression, metastasis, and worsened prognosis despite radiotherapy, endocrine therapy, or chemotherapy^\[[@R101],\ [@R103]-[@R104]\]^. From the current literature, it seems that the CD44^high^/CD24^low^/ALDH^high^ may be used for the detection of hybrid E/M CSCs.

In conclusion, while much progress has been made, targeting either epithelial or mesenchymal cancer cells seems insufficient due to cancer cell plasticity and the existence of hybrid E/M phenotype. Targeting both bulk and CSC subpopulations of epithelial, mesenchymal and hybrid E/M may be crucial for the development of clinically viable treatments to reduce resistance, relapse and metastasis.
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